Who is sponsoring NCT02920918?

NCT02920918 is sponsored by Virginia Commonwealth University.

What condition does NCT02920918 study?

NCT02920918 studies Heart Failure, Systolic, Diabetes Mellitus, Type 2.

What drugs are being tested in NCT02920918?

Interventions: Canagliflozin, Sitagliptin.

What is the status of NCT02920918?

NCT02920918 is currently COMPLETED.

Last reviewed 2019-10-28 · How we verify

A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure

NCT02920918 Phase 4 COMPLETED Results posted

Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption \[VO2\]) and ventilator efficiency (minute ventilation \[VE\]/carbon dioxide production \[VCO2\] slope) at cardiopulmonary exercise test (CPET) after 12 weeks of active treatment (primary endpoints). Blood pressure (BP), body water content, body composition, cardiac function, and diet will be also measured (secondary endpoints).

Details

Lead sponsor	Virginia Commonwealth University
Phase	Phase 4
Status	COMPLETED
Enrolment	36
Start date	2016-10
Completion	2018-09

Conditions

Heart Failure, Systolic
Diabetes Mellitus, Type 2

Interventions

Canagliflozin
Sitagliptin

Primary outcomes

Change From Baseline Aerobic Exercise Capacity at 12 Weeks — baseline and 12 weeks
Peak oxygen consumption (VO2) measured by maximal cardiopulmonary exercise test
Change From Baseline Ventilatory Efficiency at 12 Weeks — baseline and 12 weeks
Minute ventilation (VE) relative to CO2 production (VCO2) slope measured by cardiopulmonary exercise test

Countries

United States